BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 30, 2021
View Archived Issues
Boehringer Ingelheim initiates phase I study of BI-1701963 alone or in combination with BI-3011441
Read More
ERX-963 does not improve sleepiness in myotonic dystrophy type 1 patients
Read More
Enrollment opens in phase II/III study of MK-5475 in PAH
Read More
Enrollment opens in first-in-human study of OMO-103 in solid tumors
Read More
Cereno and University of Michigan collaborate on preclinical development of CS-585
Read More
Analysis of immunological and inflammatory factors associated with COVID-19 severity and progression
Read More
Xencor initiates phase I study of XmAb-564 for autoimmune diseases
Read More
X chromosome reactivation widely affects proteome
Read More
New STING receptor antagonists identified at IFM Due
Read More
Molecular Skin Therapeutics describes dual kallikrein 5/7 inhibitors
Read More
PD-1/PD-L1 interaction inhibitors identified at Bristol Myers Squibb
Read More
Recurium IP Holdings patents ERK-1 and/or ERK-2 inhibitors
Read More
Goldfinch Biopharma discovers CDK5 inhibitors
Read More
First clinical trial evaluating intravesical bacteriophage therapy for the treatment of UTIs
Read More
Atogepant statistically reduces monthly migraine days in phase III trial
Read More
First-in-class KAT6A/KAT6B inhibitor PF-9363 shows antitumor activity against ER+ breast cancer
Read More
Phase III NEPTUNO study of plitidepsin in COVID-19 receives authorization in Spain
Read More
PRT-1419 shows potent antitumor activity in preclinical models
Read More
MiR-17-92 as a therapeutic target in lupus nephritis and other autoimmune diseases
Read More
Neuromelanin MRI predicts treatment response in patients with first-episode schizophrenia
Read More
miR-206 is a prognostic marker of LGMDD2 disease progression
Read More
Phase II trial of vonoprazan regimens for H. pylori infection meets endpoints
Read More
Phase IIb/III study of masitinib in metastatic CRPC meets primary endpoint
Read More
Phase II trial evaluates ImmunityBio Anktiva with ART to inhibit HIV reservoirs
Read More
Mesoblast reports 60-day results on remestemcel-L in COVID-19 related ARDS
Read More
Preclinical through phase III, new COVID-19 therapy trials ramp up
Read More